세계의 대장암 치료제 시장 : 기회 및 전략(-2034년)

Colorectal cancer drugs refer to pharmaceutical treatments developed to prevent, manage, or cure cancer that begins in the colon or rectum. These drugs include various therapeutic approaches designed to target cancer cells, slow disease progression and improve survival rates. They play a crucial role in reducing the global burden of colorectal cancer by enhancing patient outcomes.

The global colorectal cancer drugs market reached a value of nearly $12,951.67 million in 2024, having grown at a compound annual growth rate (CAGR) of 6.74% since 2019. The market is expected to grow from $12,951.67 million in 2024 to $16,885.59 million in 2029 at a rate of 5.45%. The market is then expected to grow at a CAGR of 5.37% from 2029 and reach $21,935.16 million in 2034.

Rising Clinical Trial Activity In Pharma

During the historic period, the colorectal cancer drugs market was mainly driven by the rising clinical trial activity in pharma. An increasing number of clinical studies were registered annually, reflecting a surge in research and development efforts across various therapeutic areas. This uptick in clinical trial activity is indicative of a robust pipeline of potential therapies, signaling a dynamic and expanding pharmaceutical landscape. The growing number of clinical trials also underscores the industry's commitment to advancing medical science and addressing unmet patient needs. Moreover, the expansion of clinical trial activities has fostered greater collaboration among research institutions, healthcare providers and regulatory bodies, enhancing the overall efficiency and effectiveness of the drug development process. For example, according to ClinicalTrials.gov, a US-based government-supported database of clinical studies, in 2023, the Americas had approximately 11,974 registered clinical trials, representing 12.06% of the total trials globally. Therefore, the rising clinical trial activity in pharma significantly contributed to the growth and development of the colorectal cancer drugs market during the historic period.

Biosimilar Innovations Enhancing Accessibility And Reducing Costs In Colorectal Cancer

Companies operating in the colorectal cancer drugs market are developing biosimilars to expand treatment accessibility, lower overall therapy costs and provide affordable alternatives to high-priced biologics, while maintaining equivalent safety, efficacy and quality to the reference drugs. Biosimilars also aim to increase patient adherence by reducing financial barriers and to enable broader adoption of standard-of-care therapies in regions with constrained healthcare budgets. For example, in April 2025, Biocon Biologics, an India-based biopharmaceutical company, received approval from the Food and Drug Administration, a US-based federal agency, for Jobevne, a bevacizumab biosimilar indicated for the treatment of metastatic colorectal cancer and other cancers. Jobevne is a biosimilar to Avastin and demonstrates comparable safety, efficacy and quality, while providing a lower-cost alternative that can improve patient access and affordability. It can be used in combination with chemotherapy regimens for metastatic colorectal cancer, supporting broader adoption of standard-of-care therapies, particularly in markets with constrained healthcare budgets.

The global cs market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 47.10% of the total market in 2024.

Colorectal Cancer Drugs Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global colorectal cancer drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for colorectal cancer drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The colorectal cancer drugs market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider colorectal cancer drugs market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics: - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by cancer type, by class and by distribution channel.
• Key Trends: - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis:- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Global Market Size And Growth: - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis: - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation: - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by cancer type, by class and by distribution channel in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size And Growth: - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies:- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
• Competitive Dashboard: - Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Recent Developments:- Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for colorectal cancer drugs providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix:- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Cancer Type: Colorectal Adenocarcinoma; Gastrointestinal Carcinoid Tumors; Other Cancer Types
• 2) By Class: Targeted Therapy; Immunotherapy; Chemotherapy; Other Classes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Companies Mentioned: Merck & Co. Inc.; Amgen Inc.; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd.; Eli Lilly & Company.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; colorectal cancer drugs indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Colorectal Cancer Drugs - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Colorectal Cancer Drugs Market Definition And Segmentations
• 6.4 Market Segmentation By Cancer Type
  • 6.4.1 Colorectal Adenocarcinoma
  • 6.4.2 Gastrointestinal Carcinoid Tumors
  • 6.4.3 Other Cancer Types
• 6.5 Market Segmentation By Class
  • 6.5.1 Targeted Therapy
  • 6.5.2 Immunotherapy
  • 6.5.3 Chemotherapy
  • 6.5.4 Other Classes
• 6.6 Market Segmentation By Distribution Channels
  • 6.6.1 Hospital Pharmacies
  • 6.6.2 Retail Pharmacies
  • 6.6.3 Other Distribution Channels

7 Major Market Trends

• 7.1 Biosimilar Innovations Enhancing Accessibility And Reducing Costs In Colorectal Cancer
• 7.2 Advancing Frontline Treatment In BRAF V600E-Mutant Metastatic Colorectal Cancer
• 7.3 Combination Of EGFR Inhibitors With KRAS G12C-Targeted Agents To Overcome Resistance In Advanced Colorectal Cancer
• 7.4 Next-Generation Tyrosine Kinase Inhibitors Expanding Treatment Options In Metastatic Colorectal Cancer

8 Global Colorectal Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 8.1 Global: PESTEL Analysis
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis of End Users (B2B)
  • 8.2.1 Hospitals
  • 8.2.2 Specialty Clinics
  • 8.2.3 Cancer Treatment and Research Centers
  • 8.2.4 Homecare Settings
  • 8.2.5 Ambulatory Surgical Centers
• 8.3 Global Colorectal Cancer Drugs Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 8.4.1 Market Drivers 2019 - 2024
  • 8.4.2 Market Restraints 2019 - 2024
• 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
• 8.6 Forecast Growth Contributors/Factors
  • 8.6.1 Quantitative Growth Contributors
  • 8.6.2 Drivers
  • 8.6.3 Restraints
• 8.7 Global Colorectal Cancer Drugs Total Addressable Market (TAM)

9 Global Colorectal Cancer Drugs Market Segmentation

• 9.1 Global Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.2 Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.3 Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.4 Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Localized Or Resectable Adenocarcinoma (Stages 0-III), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.5 Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Gastrointestinal Carcinoid Tumors, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.6 Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Colorectal Cancer Drugs Market, Regional and Country Analysis

• 10.1 Global Colorectal Cancer Drugs Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Colorectal Cancer Drugs Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia Pacific Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.4 Asia Pacific Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.5 Asia Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.6 China Market
• 11.7 Summary
• 11.8 Market Overview
  • 11.8.1 Country Information
  • 11.8.2 Market Information
  • 11.8.3 Background Information
  • 11.8.4 Government Initiatives
  • 11.8.5 Regulations
  • 11.8.6 Regulatory Bodies
  • 11.8.7 Major Associations
  • 11.8.8 Taxes Levied
  • 11.8.9 Corporate Tax Structure
  • 11.8.10 Investments
  • 11.8.11 Major Companies
• 11.9 China Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.10 China Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.11 China Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.12 India Market
• 11.13 India Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.14 India Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.15 India Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.16 Japan Market
• 11.17 Summary
• 11.18 Market Overview
  • 11.18.1 Country Information
  • 11.18.2 Market Information
  • 11.18.3 Background Information
  • 11.18.4 Government Initiatives
  • 11.18.5 Regulations
  • 11.18.6 Regulatory Bodies
  • 11.18.7 Major Associations
  • 11.18.8 Taxes Levied
  • 11.18.9 Corporate Tax Structure
  • 11.18.10 Investments
  • 11.18.11 Major Companies
• 11.19 Japan Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.20 Japan Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.21 Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.22 South Korea Market
• 11.23 Summary
• 11.24 Market Overview
  • 11.24.1 Country Information
  • 11.24.2 Market Information
  • 11.24.3 Background Information
  • 11.24.4 Government Initiatives
  • 11.24.5 Regulations
  • 11.24.6 Regulatory Bodies
  • 11.24.7 Major Associations
  • 11.24.8 Taxes Levied
  • 11.24.9 Corporate Tax Structure
  • 11.24.10 Investments
  • 11.24.11 Major Companies
• 11.25 South Korea Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.26 South Korea Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.27 South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.28 Australia Market
• 11.29 Australia Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.30 Australia Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.31 Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.32 Indonesia Market
• 11.33 Indonesia Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.34 Indonesia Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.35 Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Western Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Western Europe Colorectal Cancer Drugs Market: Country Analysis
• 12.7 UK Market
• 12.8 UK Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 UK Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 Germany Market
• 12.12 Germany Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 Germany Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 France Market
• 12.16 France Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 France Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 France Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Italy Market
• 12.20 Italy Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.21 Italy Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Italy Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Spain Market
• 12.24 Spain Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.25 Spain Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Spain Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Investments
  • 13.2.11 Major companies
• 13.3 Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Eastern Europe Colorectal Cancer Drugs Market: Country Analysis
• 13.7 Russia Market
• 13.8 Russia Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 Russia Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.10 Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 North America Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 North America Colorectal Cancer Drugs Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Investments
  • 14.9.11 Major Companies
• 14.10 USA Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.11 USA Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.12 USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.17 Canada Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.18 Canada Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 South America Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 South America Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.6 Brazil Market
• 15.7 Brazil Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.8 Brazil Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Investments
  • 16.2.11 Major Companies
• 16.3 Middle East Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Middle East Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Africa Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Africa Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Merck & Co., Inc
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Business Strategy
  • 18.2.4 Financial Overview
• 18.3 Amgen Inc
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview
• 18.4 Bristol Myers Squibb Company
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Business Strategy
  • 18.4.4 Financial Overview
• 18.5 F. Hoffman-La Roche Ltd
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Business Strategy
  • 18.5.4 Financial Overview
• 18.6 Eli Lilly and Company
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Bayer AG
  • 19.1.1 Company Overview
  • 19.1.2 Products And Services
• 19.2 Takeda Pharmaceutical Company
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
• 19.3 Pfizer Inc.
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
• 19.4 Sanofi
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
• 19.5 Taiho Pharmaceutical
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
• 19.6 Johnson & Johnson
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
• 19.7 Exelixis
  • 19.7.1 Company Overview
  • 19.7.2 Products And Services
• 19.8 AstraZeneca
  • 19.8.1 Company Overview
  • 19.8.2 Products And Services
• 19.9 Daiichi Sankyo Company Limited
  • 19.9.1 Company Overview
  • 19.9.2 Products And Services
• 19.10 AkesoBio
  • 19.10.1 Company Overview
  • 19.10.2 Products And Services
• 19.11 Arcuc Bioscience
  • 19.11.1 Company Overview
  • 19.11.2 Products And Services
• 19.12 Cardiff Oncology
  • 19.12.1 Company Overview
  • 19.12.2 Products And Services
• 19.13 Shanghai Henlius Biotech
  • 19.13.1 Company Overview
  • 19.13.2 Products And Services
• 19.14 Merus
  • 19.14.1 Company Overview
  • 19.14.2 Products And Services
• 19.15 Sumitomo Pharma
  • 19.15.1 Company Overview
  • 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Sun Pharmaceutical Industries Ltd. Acquired Checkpoint Therapeutics
• 22.2 Bristol-Myers Squibb Acquired Mirati Therapeutics

23 Recent Developments In The Colorectal Cancer Drugs Market

• 23.1 Affordable Generic And Value-Based Pricing Initiatives To Lower Patient Access Barriers
• 23.2 Bristol Myers Squibb Expands Colorectal Cancer Treatment With FDA-Approved Immunotherapy
• 23.3 Targeted Combination Therapy For KRAS G12C Colorectal Cancer Gains FDA Clearance

24 Opportunities And Strategies

• 24.1 Global Colorectal Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 24.2 Global Colorectal Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 24.3 Global Colorectal Cancer Drugs Market In 2029 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies
  • 24.3.2 Competitor Strategies

25 Colorectal Cancer Drugs Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer